Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Ocrevus
|
| gptkbp:chemicalFormula |
C646H1008N178O198S4
|
| gptkbp:clinicalTrials |
Phase IV
Phase III trials MS treatment guidelines disease-modifying therapy |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
liver enzyme elevation
active infections neutropenia malignancies hypersensitivity to ocrelizumab |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:dosageForm |
1000 mg per infusion
can be increased to 300 mg/hour initially 30 mg/hour |
| gptkbp:drugInterdiction |
half-life of approximately 26 days
B cell depletion |
| gptkbp:financial_aid |
24 months
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:hasPopulation |
adults
children over 18 years |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
ocrelizumab
|
| gptkbp:insuranceAccepted |
varies by plan
|
| gptkbp:is_monitored_by |
infections
liver function tests complete blood count |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
March 2017
|
| gptkbp:mandates |
relapsing forms of multiple sclerosis
primary progressive multiple sclerosis |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:marketSegment |
ongoing studies
|
| gptkbp:offers |
high
|
| gptkbp:patentStatus |
patented
|
| gptkbp:renovated |
with sterile water for injection
|
| gptkbp:researchFocus |
autoimmune diseases
neurological disorders |
| gptkbp:route |
IV
|
| gptkbp:sideEffect |
increased risk of infections
infusion reactions hypersensitivity reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
CD20 protein
|
| gptkbp:triggerType |
depletes B cells
|
| gptkbp:usedFor |
treatment of multiple sclerosis
|
| gptkbp:weight |
146 kDa
|